PLx Pharma Inc. to Present at Piper Sandler 33rd Annual Healthcare Conference 2021
23 November 2021 - 1:15AM
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a
commercial-stage drug delivery platform technology company focused
on its clinically-validated and patent-protected PLxGuard™ that has
the potential to improve the absorption of many drugs currently on
the market and to reduce the risk of stomach injury associated with
certain drugs. The Company, with its lead products VAZALORE™ 325 mg
and VAZALORE™ 81 mg liquid-filled aspirin capsules (referred to
together as “VAZALORE”), announced today that Natasha Giordano,
President and Chief Executive Officer, and Rita O’Connor, Chief
Financial Officer, are scheduled to present virtually at the Piper
Sandler 33rd Annual Healthcare Conference 2021.
Date: |
Monday, November 22, 2021 |
Time/On Demand: |
10:00 a.m. ET |
Webcast: |
https://pipersandler.zoom.us/rec/play/sDoWhmNTPTcs-2ryqdNstA_8p5szMRwpYCiZ4yZZ0mPqzpGwYIvCugpdxgKdwx_QnBUDg8_x68njBqIt.X5bELQj2jSVlI0U3 |
The webcast of the previously recorded presentation will be
accessible on demand and archived for 90 days thereafter, via the
Company’s website at www.plxpharma.com, under the ‘Investors
Relations’ Section.
In conjunction with the Piper Sandler conference, PLx Pharma
will also conduct meetings with investors on November 30, 2021.
Meetings can be requested exclusively via Piper Sandler.
About VAZALORE VAZALORE is an FDA-approved
liquid-filled aspirin capsule, available in 81 mg and 325 mg doses.
VAZALORE delivers aspirin differently from plain and enteric coated
aspirin products. The special complex inside the capsule allows for
targeted release of aspirin, limiting its direct contact with the
stomach. VAZALORE delivers fast, reliable absorption for pain
relief plus the lifesaving benefits of aspirin. To learn more about
VAZALORE, please visit www.vazalore.com.
About PLx Pharma Inc. PLx Pharma, Inc. is
a commercial-stage drug delivery platform technology company
focused on improving how and where active pharmaceutical
ingredients (APIs) are absorbed in the gastrointestinal (GI) tract
via its clinically validated and patent protected PLxGuard™
technology. PLx believes this platform has the potential to improve
the absorption of many drugs currently on the market or in
development, and to reduce the risk of stomach injury associated
with certain drugs. To learn more about PLx Pharma Inc. and its
pipeline, please visit www.plxpharma.com.
Forward-Looking StatementsAny statements made
in this press release relating to future financial or business
performance, conditions, plans, prospects, trends, or strategies
and other financial and business matters, including without
limitation, the prospects for commercializing or selling any
products or drug candidates, are forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. In addition, when or if used in this press release, the words
“may,” “could,” “should,” “anticipate,” “believe,” “estimate,”
“expect,” “intend,” “plan,” “predict” and similar expressions and
their variants, as they relate to PLx may identify forward-looking
statements. PLx cautions that these forward-looking statements are
subject to numerous assumptions, risks, and uncertainties, which
change over time. Important factors that may cause actual results
to differ materially from the results discussed in the
forward-looking statements or historical experience include risks
and uncertainties, including the failure by PLx to secure and
maintain relationships with collaborators; risks relating to
clinical trials; risks relating to the commercialization, if any,
of PLx’s proposed product candidates (such as marketing,
regulatory, product liability, supply, competition, and other
risks); dependence on the efforts of third parties; dependence on
intellectual property, risks that PLx may lack the financial
resources and access to capital to fund proposed operations.
Further information on the factors and risks that could affect
PLx’s business, financial conditions and results of operations are
contained in PLx’s filings with the U.S. Securities and Exchange
Commission (“SEC”), which are available at www.sec.gov. Other risks
and uncertainties are more fully described in PLx’s Form 10-K for
the year ended December 31, 2020 filed with the SEC on March 12,
2021, and in other filings that PLx has made or will make going
forward. The forward-looking statements represent PLx’s estimate as
of the date hereof only, and PLx specifically disclaims any duty or
obligation to update forward-looking statements.
Contact Investor Relations:Lisa M. Wilson, In-Site
Communications, Inc.T: 212-452-2793E: lwilson@insitecony.com
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Jun 2024 to Jul 2024
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Jul 2023 to Jul 2024